125th MAINE LEGISLATURE | ||||||
LD 719 | LR 1590(04) | |||||
An Act To Make Certain Prescription Drug Disclosure Laws Consistent with Federal Law | ||||||
Fiscal Note for
Bill as Engrossed with: C "A" (H-647) |
||||||
Committee: Health and Human Services | ||||||
Fiscal Note | ||||||
Potential current biennium cost increase - General Fund | ||||||
FY 2011-12 | FY 2012-13 | Projections FY 2013-14 | Projections FY 2014-15 | |||
Appropriations/Allocations | ||||||
Other Special Revenue Funds | ($223,000) | ($223,000) | ($223,000) | ($223,000) | ||
Revenue | ||||||
Other Special Revenue Funds | ($223,000) | ($223,000) | ($223,000) | ($223,000) | ||
Fiscal Detail and Notes | ||||||
The bill makes changes to existing Maine prescription drug disclosure laws that the Department of Health and Human Services believes have helped it offset federal reductions in drug rebates for the MaineCare and other prescription drug programs. Eliminating these provisions could result in a reduction of these rebates and a net increase in program costs, the exact amount of which cannot be determined at this time. Also assumes a reduction in funding as a result of reduction in the drug trial and drug marketing programs and fees that are partially offset by the restoration of a $500 fee for the drug academic detailing program. |